Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
48
CDLX Quote, Financials, Valuation and Earnings
Last price:
$3.88
Seasonality move
:
-6.43%
Day range:
$3.77 - $3.92
52-week range:
$2.89 - $20.52
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.60x
P/B ratio:
2.82x
Volume:
392.5K
Avg. volume:
702.8K
1-year change:
-55.72%
Market cap:
$196.7M
Revenue:
$309.2M
EPS (TTM):
-$6.29
Analysts' Opinion
-
Consensus RatingCardlytics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Cardlytics has an estimated upside of 13.7% from its current price of $3.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.87.
Fair Value
-
According to the consensus of 0 analysts, Cardlytics has 13.7% upside to fair value with a price target of -- per share.
CDLX vs. S&P 500
-
Over the past 5 trading days, Cardlytics has underperformed the S&P 500 by -2.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cardlytics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cardlytics revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Cardlytics reported revenues of $67.1M.
Earnings Growth
-
Cardlytics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cardlytics reported earnings per share of -$2.90.
Enterprise value:
342.9M
EV / Invested capital:
1.21x
Price / LTM sales:
0.60x
EV / EBIT:
--
EV / Revenue:
1.17x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-12.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$127.7M
Return On Assets:
-50.62%
Net Income Margin (TTM):
-93.55%
Return On Equity:
-163.62%
Return On Invested Capital:
-67.37%
Operating Margin:
-25.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $302.5M | $302.5M | $293.5M | $79M | $67.1M | |
| Gross Profit | $113.7M | $124.3M | $127.7M | $35.8M | $28.6M | |
| Operating Income | -$118.4M | -$76.5M | -$63.1M | -$12.3M | -$16.9M | |
| EBITDA | -$74.9M | -$374.7M | -$238M | -$15.6M | -$135.3M | |
| Diluted EPS | -$3.51 | -$12.22 | -$6.29 | -$0.63 | -$2.90 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $353.9M | $335.5M | $249.1M | $205.6M | $183.3M | |
| Total Assets | $389.4M | $1.2B | $1.1B | $634.9M | $399.4M | |
| Current Liabilities | $58.3M | $274.5M | $254.9M | $179.5M | $155.9M | |
| Total Liabilities | $239.1M | $536M | $485.8M | $409.6M | $329.7M | |
| Total Equity | $150.4M | $688.6M | $580.5M | $225.3M | $69.7M | |
| Total Debt | $171.5M | $181.7M | $225.7M | $257.1M | $213.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$41.4M | -$16.2M | -$8.9M | $1.2M | $1.4M | |
| Cash From Investing | -$16M | -$11.8M | -$16M | -$3.1M | -$5.3M | |
| Cash From Financing | -$39.6M | -$20.3M | $1.7M | $21K | -$388K | |
| Free Cash Flow | -$55.1M | -$28.1M | -$27.4M | -$2M | -$3.9M | |
CDLX
Sector
Market Cap
$196.7M
$110M
Price % of 52-Week High
18.86%
66.37%
Dividend Yield
0%
0%
Shareholder Yield
-24.79%
3.39%
1-Year Price Total Return
-55.72%
-16.31%
Beta (5-Year)
1.531
0.704
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$3.73
200-day SMA
Sell
Level
$7.24
Bollinger Bands (100)
Sell
Level
3.13 - 4.63
Chaikin Money Flow
Buy
Level
31M
20-day SMA
Buy
Level
$3.84
Relative Strength Index (RSI14)
Buy
Level
51.12
ADX Line
Buy
Level
13.21
Williams %R
Neutral
Level
-43.2749
50-day SMA
Sell
Level
$3.94
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
60.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.2999)
Sell
CA Score
(Annual)
Level (-2.2281)
Buy
Beneish M-Score
(Annual)
Level (-3.5889)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (4.6459)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K., and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.
Stock Forecast FAQ
In the current month, CDLX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CDLX average analyst price target in the past 3 months is --.
-
Where Will Cardlytics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cardlytics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Cardlytics?
Analysts are divided on their view about Cardlytics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cardlytics is a Sell and believe this share price will drop from its current level to --.
-
What Is Cardlytics's Price Target?
The price target for Cardlytics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CDLX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cardlytics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CDLX?
You can purchase shares of Cardlytics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cardlytics shares.
-
What Is The Cardlytics Share Price Today?
Cardlytics was last trading at $3.88 per share. This represents the most recent stock quote for Cardlytics. Yesterday, Cardlytics closed at $3.87 per share.
-
How To Buy Cardlytics Stock Online?
In order to purchase Cardlytics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
